Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.216 EUR | -1.82% | -.--% | -82.78% |
May. 28 | Mithra Delays AGM Amid Monetization Process | MT |
Apr. 29 | Mithra Pharmaceuticals to Postpone the Publication of Its Annual Report 2023 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-82.78% | 16.19M | C+ | ||
-2.29% | 89.87B | A- | ||
-3.95% | 37.57B | A- | ||
-13.07% | 32.75B | B- | ||
+63.05% | 26.47B | A | ||
-22.14% | 14.25B | C | ||
-7.96% | 12.99B | B- | ||
-9.33% | 11.93B | D+ | ||
-46.33% | 10.84B | B | ||
+5.77% | 9.11B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
- Stock Market
- Equities
- MITRA Stock
- Ratings Mithra Pharmaceuticals S.A.